Dyadic Interventions on Diabetes Self-Management and Glycemic Control for Adults With Type 2 Diabetes: A Systematic Review.

Sci Diabetes Self Manag CareAug 31, 2026 (epub)
Clinical ResearchEndocrinology

Yuqing Zhang, Hyeyeon Shin, Fuad Alhorani et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effectiveness of family-dyad interventions on diabetes self-management and glycemic control in adults with Type 2 diabetes. A total of 23 studies were included, revealing mixed results in diabetes control outcomes, particularly A1C levels, and short-term improvements in behavioral and psychosocial measures. The review highlights the need for further research to strengthen evidence in this area.

Key findings

  • 23 studies were included in the final review, with mixed results on diabetes control outcomes.
  • Half of the included studies were pilot studies assessing feasibility and acceptability.
  • Short-term efficacy was noted in behavioral and psychosocial measurements like self-efficacy.

Why it matters

Understanding the impact of family-dyad interventions on diabetes management can inform clinicians about potential support strategies for patients, enhancing self-management and possibly improving glycemic control.

Source

PubMed · PMID 42670748

Published in Sci Diabetes Self Manag Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.